摘要
目的 明确胃癌和结直肠癌患者血清瘦素、脂联素表达水平变化及其与发病的相关性。方法 连续纳入2015年4月1日至2016年1月31日期间胃癌患者53例，结直肠癌患者48例，非肿瘤对照组患者56例，检测血清瘦素和脂联素表达水平，比较胃癌、结直肠癌组与非肿瘤对照组的血清瘦素和脂联素的表达变化，并进行相对危险度及相关性分析。结果 对人口学特征及疾病特征比较后发现，三组患者在性别（χ2=27.353， P=0.000）、年龄（χ2=9.953， P=0.007）、受教育程度（χ2=27.527， P=0.000）及肿瘤家族史（χ2=133.503， P=0.000）方面存在差异。与非肿瘤对照组比较，胃癌组患者血清瘦素表达水平升高［（6.02±1.83） vs (4.76±1.62)， P=0.013］、结直肠癌组患者血清瘦素表达水平升高［（6.21±1.74） vs （4.76±1.62）， P=0.006］；胃癌组患者血清脂联素表达水平降低［（4.43±0.48）vs （4.90±0.39）， P=0.000］、结直肠癌组患者血清脂联素表达水平降低［（4.41±0.42） vs （4.90±0.39）， P=0.000］。按病理分型对数据进行分层比较，高、中、低分化三组间无统计学差异。按肿瘤不同分期进行分层比较，早期与中晚期肿瘤两组数据间无统计学差异。将胃癌、结直肠癌组与非肿瘤对照组患者血清瘦素、脂联素水平按照四分位数分层后，进行相对危险度分析，胃癌、结直肠癌组血清瘦素风险比值分别为3.51和9.23，血清脂联素OR值分别为0.20和0.07。结论 血清瘦素水平升高是胃癌、结直肠癌发病的风险因素，血清脂联素水平是胃癌、结直肠癌发病的保护因素，血清脂联素水平的降低增加了胃癌、结直肠癌的发病风险。血清瘦素、脂联素水平变化可能与胃癌、结直肠癌的发病相关。
Abstract
Objective To determine the changes of serum leptin and adiponectin levels in patients with gastric cancer and colorectal cancer and their correlation with pathogenesis. Methods A total of 53 patients with gastric cancer， 48 patients with colorectal cancer， and 56 patients with non-tumor control were enrolled in the period from April 1， 2015 to January 31， 2016. Serum leptin and adiponectin were detected. Serum leptin and adiponectin expression in gastric cancer， colorectal cancer and non-tumor control groups were compared， and relative risk and correlation analysis were performed. Result After comparing the demographic characteristics and disease characteristics， the three groups of patients were found that have significant difference in gender (χ2=27.353， P=0.000)， age (χ2=9.953， P=0.007)， and education level (χ2=27.527， P=0.000)， the family history of the tumor (χ2=133.503， P=0.000). Compared with the non-tumor control group， the serum leptin expression level was increased in the gastric cancer group ［(6.02±1.83) vs (4.76±1.62)， P=0.013］， and the serum leptin expression level was increased in the colorectal cancer group ［(6.21±1.74) vs (4.76±1.62)， P=0.006］； serum adiponectin expression decreased in patients with gastric cancer ［(4.43±0.48) vs (4.90±0.39)， P=0.000］， and serum adiponectin expression decreased in patients with colorectal cancer ［(4.41±0.42) vs (4.90±0.39)， P=0.000］. The data were stratified by pathological classification， and there was no statistical difference between the three groups of high， medium and low differentiation. There were no statistical differences between the two groups in the early and middle-stage tumors. The serum leptin levels and adiponectin levels in the gastric cancer， colorectal cancer and non-tumor control groups were stratified by quartiles， and the relative risk analysis was performed. The serum leptin odds ratio (OR) of gastric cancer and colorectal cancer group OR values were 3.51 and 9.23， and the serum adiponectin OR values were 0.20 and 0.07. Conclusion Elevated serum leptin level is a risk factor for gastric cancer and colorectal cancer. Serum adiponectin level is a protective factor for gastric cancer and colorectal cancer， but the decrease of serum adiponectin level will increases gastric cancer and colorectal cancer’s risk of onset. Changes in serum leptin and adiponectin levels may be associated with the pathogenesis of gastric cancer and colorectal cancer.
关键词
胃癌 /
结直肠癌 /
脂代谢 /
瘦素 /
脂联素
Key words
Gastric cancer /
Colorectal cancer /
Lipid metabolism /
Leptin /
Adiponectin
1马翠翠，2李杨，3庞向鹏，3娄婷婷，1王欢，1郭瑞芳，4刘亚航.
胃癌、结直肠癌患者血清瘦素和脂联素变化及相关性分析[J]. 肿瘤代谢与营养电子杂志. 2019, 6(3): 351-356 https://doi.org/10.16689/j.cnki.cn11-9349/r.2019.03.016
1MA Cui-cui， 2LI Yang， 3PANG Xiang-peng， 3LOU Ting-ting，1WANG Huan， 1GUO Rui-fang， 4LIU Ya-hang.
Changes and correlation analysis of serum leptin and adiponectin expression in patients with gastric and colorectal cancer[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2019, 6(3): 351-356 https://doi.org/10.16689/j.cnki.cn11-9349/r.2019.03.016
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1.石汉平. 肿瘤是一种代谢性疾病. 肿瘤代谢与营养电子杂志. 2018;5(2):111-115.
2.Couraud S， Gerard-Zalcman G， Milleron B， et al. Lung cancer in never smokers-a review. Eur J Cancer. 2012;48(9):1299-1311．
3.石红兵， 蒋敬庭， 吴昌平. 胃癌患者血脂变化及总胆固醇的临床意义. 临床肿瘤学杂志. 2011;16(8):686-688.
4.Scherer T， Lehnert H， Hallschmid M. Brain insulin and leptin signaling in metabolic control: from animal research to clinical application. Endocrinol Metab Clin North Am. 2013;42(1):109-125.
5.Kralisch S， Sommer G， Deckert CM， et al. Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol. 2007;32(3):161-171.
6.Wei EK， Giovannucci E， Fuchs CS， et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688-1694.
7.Chen DC， Chung YF，Yeh YT， et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237(1):109-114.
8.Ishikawa M，Kitayama J， Kazama S， et al. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11(2 Pt 1):466-472.
9.Hanahan D， Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
10.Nomura DK，Cravatt BF. Lipid metabolism in cancer. Biochim Biophys Acta. 2013;1831(10):1497-1498.
11.Currie E， Schulze A，Zechner R， et al. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153-161.
12.Torre LA， Bray F， Siegel RL， et al. Global cancer statistics.CA Cancer J Clin. 2015;65(2):87-108.
13.王增， 蔡鑫君， 刘孟娟， 等. 年龄、性别及2型糖尿病对于胃癌发生的风险:一项单一机构的回顾性分析(英文). J PHARM SCI-China. 2014;23(11):799-803.
14.丁兰君， 赵丽中， 王媛， 等. 中国结直肠癌健康风险评估模型研究. 中国慢性病预防与控制. 2018;26(5):325-328.
15.Shida D， Kitayama J， Mori K， et al. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells．Cancer Res. 2005;65(20):9159-9163．
16.范晓琳， 张鹏飞， 王静， 等. 瘦素系统在胃癌组织表达及与临床病理特征关系. 青岛大学医学院学报. 2016;52(2):223-225.
17.李福琴， 陈奎生， 张国俊. 瘦素受体在胃癌组织的表达及转移作用. 医药论坛杂志. 2006;27(21):39-41.
18.贾淑云，贾红云. 瘦素与胃癌的关系. 宁夏医学杂志. 2008;9:859-860.
19.蔡元浩，戴永江.瘦素及其受体在胃癌粘膜组织中的表达及分析.四川医学.2009;30(9):1405-1406.
20.邹辉， 蒲志忠， 唐彩益. 瘦素及其受体在结直肠癌和转移性结直肠癌中的表达及临床意义. 现代医药卫生. 2017;33(13):2031-2033.
21.刘晖， 徐渭贤， 曹丽静， 等. 瘦素、瘦素受体、VEGF和CD34在结直肠癌中的表达及其生物学意义. 河北医科大学学报. 2009;30(7):673-676.
22.江勇，谭卫林，韩潞，等.结直肠癌患者血清脂联素瘦素及其受体表达与临床病理参数的关系. 河北医学. 2018;24(7):1121-1125.
23.向德森，黄俊，熊亚立.瘦素与结直肠癌发生的相关性研究进展.重庆医学.2017;46(24):3427-3430.
24.池肇春. 脂联素生物学与消化系统肿瘤. 胃肠病学. 2016;21(7):439-441.
25.郭晓红， 张军林， 吴明煜. 脂联素抗消化系统肿瘤的研究进展. 基础医学与临床. 2015;35(5):707-710.
26.Tsukada T， Fushida S， Harada S， et al. Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res. 2011;30:107.
27.Seker M， Bilici A， Sonmez B， et al. The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol. 2010;27(4):1319-1323.
28.冯玉良，戴一扬，郑培奋，等.血清脂联素水平与胃癌转移的相关性研究.实用医学杂志.2011;27(6):976-978.
29.Catalán V， Gómez-Ambrosi J，Ｒodríguez A， et al. Upregulation of the novel proinflammatory adipokines lipocalin-2， chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem. 2011;22(7):634-641.
30.解寒冰， 夏云展， 薛建锋， 等. 脂联素在结直肠癌患者中的表达及其对结直肠癌细胞增殖和Caspase-3表达的影响. 中国现代医学杂志. 2016;26(19):47-51.
31.苗爱峰，俞林.脂联素与结直肠癌的相关性研究进展.结直肠肛门外科. 2013;19(1):65-68.
32.Song M， Gong J， Giovannucci EL， et al. Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer. 2015;137(1):154-164.
33.Joshi ＲK， Lee SA. Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(1):397-405.
34.祁绍艳， 李继昌， 柯楠. 瘦素和细胞外信号调节激酶2在胃癌及癌前病变中的表达及意义. 临床荟萃. 2008;7:499-500.
35.王俊江， 周天羽， 张扬， 等. 脂联素在高-中分化结直肠癌癌组织及癌旁组织中的表达规律. 辽宁中医药大学学报. 2012;14(6):229-231.
36.梁晶晶， 冯奕习， 彭伟如， 等. 脂联素联合瘦素对结直肠癌高危人群早期筛查的临床研究. 系统医学. 2018;3(17):7-9.
基金
内蒙古自治区科技计划项目（2016020978）；内蒙古自治区自然科学基金（2016MS0870）；内蒙古自治区人民医院科研基金（201502）
PDF(522 KB)
